IDH1 and glioblastoma: Apart from necessary determination of isocitrate dehydrogenase (IDH) status and chromosomal 1p/19q co-deletion, several other markers can be considered for routine examination, namely, assessment of telomerase reverse transcriptase promoter (TERTp), B-Raf (BRAF), and H3F3A mutations (2).Among these diagnostic and prognostic indicators, mutated TERTp is frequently observed in adult IDH-wild-type GBM, which involves telomere stabilization, tumor immortality, and progression (3–5).